Human Norovirus Molecular Analysis and Development of Norovirus Vaccine
Downloads
The most common organism of acute viral gastroenteritis is norovirus, which accounts for roughly 20% of all occurrences of acute gastroenteritis globally. The virus kills over 200,000 children each year and is the leading cause of childhood diarrhea in the rotavirus-vaccinated population. This study aims to review available studies regarding the information on the genogroup norovirus in humans, development of norovirus vaccines, and effectiveness of norovirus vaccines. A systematic review using Science Direct, PubMed, and Scopus databases to identify eligible case studies. The search was conducted in September-October 2021. The quality of the included literature used checklists from the Critical Appraisal Skills Program (CASP). All of the six selected studies with populations given RT-PCR intervention showed positive for norovirus infection. The most predominant genogroups in humans are GI and GII. As for the research results of the two selected studies on norovirus vaccine, namely the human phase 2 trial containing two Virus-Like Particles (VLP) genotypes, one study showed efficacy at 18-49 one study at ≥ 60 years of age. This study analysis uses Takeda bivalent vaccine. The vaccine includes norovirus antigens of the GI and GII genogroups, intending to expand its protective immune potential. GI, GII, and GIV genogroups are prevalent in humans. VLP that contains GI.I and consensus GII.4c have been created as the NoV vaccine, providing signiï¬ cant efficacy. Very likely because they contain GI dan GII antigens, which are the genogroups that infect humans the most. Patients given a placebo developed acute gastroenteritis due to norovirus GII.2, indicating a genotype cross-reactivity.
Weinberg GA. Outbreak Epidemiology: One of Many New Frontiers of Norovirus Biology. J Infect Dis. 2019;219(9):1349–1352.
Athiyyah AF, Wardhani S, Darma A, Ranuh RG, Raharjo D, Shirakawa T, et al. The Clinical Epidemiology Of Norovirus Infection In Children With Diarrhea At Regional Public Hospital Dr. Soetomo. J Berk Epidemiol. 2020;8(3):200–7.
Utsumi T, Lusida MI, Dinana Z, Wahyuni RM, Yamani LN, Juniastuti, et al. Occurrence of norovirus infection in an asymptomatic population in Indonesia. Infect Genet Evol. 2017;55:1–7.
Cannon JL, Lopman BA, Payne DC, Vinjé J. Birth cohort studies assessing norovirus infection and immunity in young children: a review. Clin Infect Dis. 2019;69(2):357–65.
Vinjé J. Advances in Laboratory Methods for Detection and Typing of Norovirus. J Clin Microbiol. 2014;53:373–381.
Kim JS, Kim HS, Hyun J, Kim HS, Song W. Molecular epidemiology of human norovirus in Korea in 2013. Biomed Res Int. 2015;2015.
Qi R, Huang YT, Liu JW, Sun Y, Sun XF, Han HJ, et al. Global Prevalence of Asymptomatic Norovirus Infection: A Meta-analysis. EClinicalMedicine. 2018;2–3:50–8.
Cates J, Vinjé J, Parashar U, Hall A. Recent advances in human norovirus research and implications for candidate vaccines. Expert Rev Vaccines. 2020;19(6):539–48.
World Health Organization. Introduksi Keamanan Vaksin [Internet]. in.vaccine-safety-training.org. 2021 [cited 2021 Dec 20]. Available from: https:// in.vaccine-safety-training.org/pre-licensure-vaccine-safety.html
Nordgren J, Svensson L. Genetic susceptibility to human norovirus infection: an update. Viruses. 2019;11(3):226.
Wulandari PS, Juniastuti, Wahyuni RM, Amin M, Yamani LN, Qushai M, et al. Predominance of norovirus GI.4 from children with acute gastroenteritis in Jambi, Indonesia, 2019. J Med Virol. 2020;92(12):3165– 3172.
Robilotti E, Deresinski S, Pinsky BA. Norovirus. Clin Microbiol Rev. 2015;28(1):134–64.
Lopman BA, Steele D, Kirkwood CD, Parashar UD. The Vast and Varied Global Burden of Norovirus: Prospects for Prevention and Control. PLoS Med. 2016;13(4):e1001999.
Cortes-Penï¬eld NW, Ramani S, Estes MK, Atmar RL. Prospects and Challenges in the Development of a Norovirus Vaccine. Clin Ther. 2017;39(8):1537– 1549.
Uman L. Systematic Reviews and Meta-Analyses', J. Can. Acad. Child Adolesc. Psychiatry. 2011;20:57–9.
Torén K, Schiöler L, Nenonen N, Hannoun C, Roth A, Andersson LM, et al. Risk factors for norovirus infection in healthcare workers during nosocomial outbreaks: a cross-sectional study. Antimicrob Resist Infect Control. 2021;10(1):1–9.
John JL, Mori D, Amit LN, Mosiun AK, Chin AZ, Ahmed K. High proportion of norovirus infection and predominance of GII. 3 [P12] genotype among the children younger than 5 in Sabah, Malaysian Borneo. J Clin Virol. 2021;143, 104968.
Cao R, Ma X, Li W, Wang B, Yang Y, Wang H, et al. Epidemiology of norovirus gastroenteritis in hospitalized children under ï¬ve years old in western China', 2015–2019,. J Microbiol Immunol Infect. 2021;
Bonura F, Urone N, Bonura C, Mangiaracina L, Filizzolo C, Sciortino G, et al. Recombinant GII. P16 genotype challenges RT-PCR-based typing in region A of norovirus genome',. J Infect. 2021.
Utsumi T, Lusida M, Dinana Z, Wahyuni R, Soegijanto S, Soetjipto. Molecular epidemiology and genetic diversity of norovirus infection in children hospitalized with acute gastroenteritis in East Java, Indonesia in 2015–2019. Infect Genet Evol. 2021;88:104703.
Shen W, Sheng Y, Weng J, Li G, Wang D, Qiu D, et al. Molecular epidemiology of norovirus associated with acute gastroenteritis in Taizhou, China: A retrospective study. J Infect Public Health. 2020;13(1):34–9.
Sherwood J, Mendelman P, Lloyd E, Liu M, Boslego J, Borkowski A, et al. Efficacy of an intramuscular bivalent norovirus GI. 1/GII. 4 virus-like particle vaccine candidate in healthy US adults. Vaccine. 2020;38(41):6442–9.
Treanor J, Sherwood J, Cramer J, Le Cam Bouveret N, Lin S, Baehner F, et al. A phase 2 study of the bivalent VLP norovirus vaccine candidate in older adults; impact of MPL adjuvant or a second dose. Vaccine. 2020;38(36):5842–5850.
Capece G, Gignac E. Norovirus. Treasure Island (FL), editor. StatPearls: StatPearls Publishing; 2021.
Esposito S, Principi N. Norovirus Vaccine: Priorities for Future Research and Development. Front Immunol. 2020;11:1383.
Copyright (c) 2022 Indonesian Journal of Tropical and Infectious Disease
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The Indonesian Journal of Tropical and Infectious Disease (IJTID) is a scientific peer-reviewed journal freely available to be accessed, downloaded, and used for research. All articles published in the IJTID are licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which is under the following terms:
Attribution ” You must give appropriate credit, link to the license, and indicate if changes were made. You may do so reasonably, but not in any way that suggests the licensor endorses you or your use.
NonCommercial ” You may not use the material for commercial purposes.
ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
